- Home
- DCOM vs ETON Comparison
DCOM vs ETON Comparison
Compare DCOM & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCOM | ETON |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DCOM | ETON |
|---|---|---|
| Price | $38.61 | $49.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $46.00 | ★ $71.50 |
| AVG Volume (30 Days) | 298.5K | ★ 529.8K |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 329.09 | N/A |
| EPS | ★ 1.49 | 0.41 |
| Revenue | $19,907,000.00 | ★ $79,950,000.00 |
| Revenue This Year | $14.41 | $87.26 |
| Revenue Next Year | $10.39 | $47.21 |
| P/E Ratio | ★ $26.09 | $122.44 |
| Revenue Growth | 19.03 | ★ 104.94 |
| 52 Week Low | $25.63 | $14.27 |
| 52 Week High | $41.97 | $66.37 |
Technical Indicators
Market Signals| Indicator | DCOM | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 34.35 |
| Support Level | $38.38 | $48.79 |
| Resistance Level | $41.45 | $50.18 |
| Average True Range (ATR) | 0.68 | 3.37 |
| MACD | -0.02 | -0.71 |
| Stochastic Oscillator | 42.18 | 4.87 |
Price Performance
Historical ComparisonAbout DCOM Dime Community Bancshares Inc.
Dime Commercial Bancshares Inc is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.